10-Q: Integer Holdings Corp. Reports Q2 2026 Results Amidst Acquisition News

Integer Holdings Corporation's Q2 2026 results show a decline in sales and profitability, alongside significant restructuring charges and the announcement of a pending acquisition by KKR.

Summary

• Integer Holdings Corporation reported a decrease in sales and gross profit for the second quarter and first six months of 2026 compared to the prior year.
• Operating expenses increased, primarily due to higher SG&A and restructuring charges.
• The company announced a definitive agreement to be acquired by an affiliate of Kohlberg Kravis Roberts & Co. L.P. for $127 per share in cash.
• Restructuring and other charges significantly increased, including a $5.9 million fixed asset impairment charge.
• The company's effective tax rate saw a notable decrease due to various tax credits and international tax rules.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant decrease in sales and gross profit, coupled with an increase in operating expenses and a pending acquisition that introduces uncertainty.

Positives

• The company maintained compliance with its financial covenants under the Senior Secured Credit Facilities.
• Cash flow from operations increased to $84.4 million for the first six months of 2026 from $75.1 million in the prior year period.
• The company has $100 million of capacity remaining under its share repurchase program.
• The acquisition by KKR offers a premium of $127 per share in cash for common stock.

Negatives

• Sales for the second quarter and first six months of 2026 decreased by $12.4 million and $10.2 million, respectively, compared to the same periods in 2025.
• Gross profit decreased by $16.2 million and $26.9 million for the respective periods due to lower fixed cost absorption.
• Operating expenses increased by $8.6 million and $15.6 million for the respective periods.
• Restructuring and other charges increased significantly by 256.0% in the second quarter and 51.6% in the first six months.
• The company experienced lower than anticipated market adoption for three new products, impacting sales.
• The pending acquisition introduces uncertainty and potential disruptions to business relationships and operations.

Risks

• Risks related to the pending Merger, including potential delays, failure to complete, and adverse effects on stock price and business relationships.
• Operational risks such as dependence on a limited number of customers, pricing pressures, reliance on third-party suppliers, and supply chain disruptions.
• Strategic risks including intense competition, R&D investment recovery, and the ability to respond to technological changes.
• Market, financial, and indebtedness risks, including volatility of stock price, significant outstanding indebtedness, and potential conversion of convertible notes.
• Legal and compliance risks, including ongoing litigation and regulatory changes in the healthcare industry.
• The potential for disruption of management time and resources due to the Merger.
• Uncertainty regarding the outcome of the Merger could affect employee retention and recruitment.
• Restrictions on business activities due to the Merger Agreement could prevent pursuing attractive opportunities.

Future Outlook

The company expects year-over-year sales growth in 2026 to be impacted by lower sales related to three new products due to lower than anticipated market adoption. The pending acquisition by KKR is a significant event that will transform the company into a privately held entity.

Management Comments

• "Sales for the second quarter and first six months of 2026 decreased $12.4 million and $10.2 million, respectively, when compared to the same periods in 2025, driven by lower Cardio & Vascular and Other Markets sales, partially offset by higher Cardiac Rhythm Management & Neuromodulation sales."
• "Gross profit for the second quarter and first six months of 2026 decreased $16.2 million and $26.9 million, respectively, primarily driven by lower fixed cost absorption due to lower production volumes."
• "Operating expenses for the second quarter and first six months of 2026 increased $8.6 million and $15.6 million, respectively, when compared to the same periods in 2025, primarily due to higher SG&A expenses and Restructuring and other charges."
• "We continuously evaluate our business and identify opportunities to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs."

Industry Context

StockSavvy.ai notes that Integer Holdings operates in the highly competitive medical device contract development and manufacturing sector. The recent acquisitions of Precision Coating, VSi Parylene, and Biocoat indicate a strategy to expand technological and manufacturing capabilities. However, the reported sales decline and increased restructuring charges suggest challenges in market adoption and operational efficiency, which are critical factors in this industry.

Comparison to Industry Standards

• The decline in gross margin to 24.3% in Q2 2026 from 27.1% in Q2 2025, attributed to lower fixed cost absorption, is a concern. Industry benchmarks for medical device contract manufacturers can vary, but consistent margin erosion typically signals competitive pressure or operational inefficiencies.
• The significant increase in restructuring and other charges, including a $5.9 million fixed asset impairment, suggests a need for significant operational adjustments. Companies in this sector often face pressure to optimize manufacturing footprints and supply chains, but such large charges can indicate underlying issues.
• The announcement of a pending acquisition by KKR at a premium of $127 per share suggests that the market (or a sophisticated financial buyer) values the company's assets and potential, despite the recent operational headwinds. This valuation needs to be assessed against comparable transactions in the medical device CDMO space.

Legal Proceedings

• A putative class action lawsuit (Pembroke Pines Pension Fund for Firefighters and Police Officers v. Integer Holdings Corporation) alleging violations of securities laws in public disclosures was dismissed, but the plaintiff has filed a notice of appeal.

Stakeholder Impact

• Shareholders will receive $127 per share in cash upon completion of the acquisition, delisting the company from the NYSE.
• Employees may face uncertainty regarding job security and roles post-acquisition.
• Customers may experience changes in service or product offerings due to the acquisition and ongoing operational adjustments.
• Suppliers may face altered business relationships and contract terms under new ownership.

Next Steps

• Complete the acquisition by Armstrong Parent, Inc. (KKR) for $127 per share, subject to customary closing conditions and stockholder approval.
• Continue to manage operational costs and pursue cost reduction initiatives.
• Address challenges related to new product market adoption.
• Integrate recent acquisitions (Precision Coating, VSi Parylene, Biocoat) effectively.

Key Dates

Recommendation

The company's recent financial performance shows a decline in sales and profitability, coupled with increased restructuring costs. While the pending acquisition by KKR at a premium offers a clear exit for shareholders, the operational challenges and integration risks warrant a cautious approach. The 'hold' recommendation reflects the uncertainty surrounding the successful integration of recent acquisitions and the execution of future strategies post-acquisition, balanced by the certainty of the cash offer.

Keywords

medical device manufacturing, contract development, cardio vascular, neuromodulation, cardiac rhythm management, acquisition, KKR, performance-based stock units